Last reviewed · How we verify

Uncomplicated Urinary Tract Infections — Treatment Landscape & Competitive Intelligence

Uncomplicated Urinary Tract Infections (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Uncomplicated Urinary Tract Infections, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Test formulation (Treatment A) test-formulation-treatment-a Pfizer Enzyme inhibitor Specific enzyme Not yet determined
Blujepa GEPOTIDACIN Glaxosmithkline 2025-01-01
Various various Pfizer Antibiotic Not specified

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Uncomplicated Urinary Tract Infections
  2. Glaxosmithkline · 1 drug in Uncomplicated Urinary Tract Infections

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Uncomplicated Urinary Tract Infections:

Cite this brief

Drug Landscape (2026). Uncomplicated Urinary Tract Infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/uncomplicated-urinary-tract-infections. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing